Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277461 | 0.93 | MAPK14 (0.58) | MAPK14HSP90AB1 | |
| SCHEMBL5224292 | 0.89 | MAPK14 (0.53) | MAPK14HSP90AB1MAPK11 | |
| SCHEMBL5225374 | 0.87 | MAPK14 (0.52) | MAPK14HSP90AB1MAPK11 | |
| SCHEMBL5226163 | 0.85 | MAPK14 (0.60) | MAPK14HSP90AB1MAPK11 | |
| SCHEMBL3282615 | 0.84 | MAPK14 (0.67) | MAPK14MAPK11 | |
| SCHEMBL5225468 | 0.83 | MAPK14 (0.60) | MAPK14MAPK11 | |
| SCHEMBL5228702 | 0.81 | MAPK14 (0.49) | MAPK14MAPK11 | |
| SCHEMBL5228281 | 0.80 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL5225768 | 0.79 | MAPK14 (0.44) | MAPK14HSP90AB1MAPK11 | |
| SCHEMBL5225567 | 0.79 | MAPK14 (0.44) | MAPK14HSP90AB1MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1842851-A2 | Novel compounds | Smithkline Beecham Corporation (US) | 2007-10-10 | — | — | EP | claimed |
| US-7235551-B2 | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-26 | — | — | US | claimed |
| EP-1265900-B1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D|PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2007-05-16 | — | — | EP | claimed |
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | GLAXOSMITHKLINE LLC | 2003-05-29 | — | — | US | claimed |
| EP-1842851-A2 | Novel compounds | Smithkline Beecham Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1265900-B1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO 4,5-D|PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100756-A1 | 1,5- disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | MAPKAPK2, MAPK4, MAP4K2 | MAPK14 42/4885HSP90AB1 329/4885MAPK11 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.